$1.3 Billion is the total value of FRAZIER MANAGEMENT LLC's 43 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $33,362,000 | -49.4% | 1,747,622 | -34.7% | 2.57% | -51.3% |
| ALNA | Sell | ALLENA PHARMACEUTICALS | $978,000 | -67.5% | 1,651,357 | -50.4% | 0.08% | -68.8% |
| FRLN | Exit | FREELINE THERAPEUTICS HLDGSsponsored ads | $0 | – | -550,000 | -100.0% | -0.15% | – |
| GRTX | Exit | GALERA THERAPEUTICS INC | $0 | – | -241,000 | -100.0% | -0.16% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -433,247 | -100.0% | -0.21% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -3,123,107 | -100.0% | -4.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-08
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.